3상모집 중

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

연구 개요

The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.

스폰서: 리드: 일라이 릴리
적응증: Crohn's Disease, Obesity or Overweight
중재: Mirikizumab, Mirikizumab, Tirzepatide, Placebo
목표 등록: 290명
시작일: 2025-06-26
완료(예정): 2028-05-01
등록번호: NCT06937099 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.